Results 181 to 190 of about 371,644 (221)

Impact of Anti-HER2 Therapies on Overall Survival in Patients with HER2-Positive Metastatic Breast Cancer: Focusing on Intracranial Efficacy of Emerging Treatments. [PDF]

Cancers (Basel)
Drittone D, Lucci C, Esposito L, Mazzuca F, Pisegna S.   +4 more
europepmc   +1 more source

Highly Active Cu14 Cluster Precisely Activates Autophagy Inhibitor to Amplify Cuproptosis Immunotherapy

Advanced Science, EarlyView.
An atomically precise Cu14 cluster‐mediated bond scission reaction pioneers the amplification of the antitumor immune response via synergetic cuproptosis‐associated immunogenic cell death induction and in situ autophagy blockade. ABSTRACT Transition metal‐mediated cleavage mechanisms have emerged as an effective means to mitigate the off‐target ...
Qiu‐Xu Zang, Wei‐Tong Chen, Yu‐Ying Shen, Zhao‐Yang Wang, Kai Li, Xueli Zhao, Yanjuan Sang, Xiaoyuan Chen, Shuang‐Quan Zang   +8 more
wiley   +1 more source

Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan. [PDF]

Breast Cancer
Tsurutani J, Noguchi K, Tanabe A.
europepmc   +1 more source

BLADE‐ON‐PETIOLE Genes Enable Genetic Bottleneck Mitigation Through Cross‐Species Repurposing of Floral Persistence Traits

Advanced Science, EarlyView.
This study shows that BLADE‐ON‐PETIOLE (BOP) proteins regulate floral abscission and senescence in tomato by interacting with TFAM1 to form transcriptional condensates controlling the ARABIDOPSIS THALIANA HOMEOBOX GENE 1 (ATH1)‐mediated abscission pathway.
Nan Xiao, Qianwen Lyu, Tinghao Zhang, Yupan Zou, Yue Xie, Dandan Yang, Cao Xu, Xiaozhen Huang   +7 more
wiley   +1 more source

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. [PDF]

Nat Med
Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D.   +24 more
europepmc   +1 more source

Reply to "Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions" and "The Role of HER2 PET in Treatment of Breast Cancer". [PDF]

J Nucl Med
Yeh R.
europepmc   +1 more source

DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer. [PDF]

Transl Breast Cancer Res
Li J, Hao C, Wang H, Pan Y, Jiang Z.
europepmc   +1 more source

Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives. [PDF]

Antibodies (Basel)
Balata A, Pogoda K.
europepmc   +1 more source